Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

What were the key financial metrics reported for Q2 2025 and how do they compare to the previous quarter? Did the company provide any guidance or outlook for future quarters, and what does that imply for earnings expectations? What specific corporate updates were announced, and could they impact the company's strategic positioning or growth prospects? Are there any notable changes in revenue composition (e.g., product lines, geographic regions) that could influence future performance? How does Opus Genetics' Q2 performance compare to its main competitors in the biotech/genomics sector? Did the release mention any new partnerships, collaborations, or licensing agreements that could drive future revenue? What technical indicators or chart patterns are emerging following the release that might inform short‑term trading strategies? How might the Q2 results affect the valuation multiples (e.g., P/E, EV/EBITDA) for Opus Genetics? What is the market's reaction to the earnings release (e.g., price movement, volume) and does it suggest a shift in sentiment? Are there any risks or uncertainties highlighted in the corporate update that could affect the stock's upside potential?